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Abstract
Helicobacter suis (H. suis) is a widespread porcine gastric pathogen, which is also of zoo-
notic importance. The first goal of this study was to investigate the efficacy of several vac-
cine adjuvants (CpG-DNA, Curdlan, Freund’s Complete and Incomplete, Cholera toxin),
administered either subcutaneously or intranasally along with H. suis whole-cell lysate, to
protect against subsequent H. suis challenge in a BALB/c infection model. Subcutaneous
immunization with Freund’s complete (FC)/lysate and intranasal immunization with Cholera
toxin (CT)/lysate were shown to be the best options for vaccination against H. suis, as deter-
mined by the amount of colonizing H. suis bacteria in the stomach, although adverse effects
such as post-immunization gastritis/pseudo-pyloric metaplasia and increased mortality
were observed, respectively. Therefore, we decided to test alternative strategies, including
sublingual vaccine administration, to reduce the unwanted side-effects. A CCR4 antagonist
that transiently inhibits the migration of regulatory T cells was also included as a new adju-
vant in this second study. Results confirmed that immunization with CT (intranasally or sub-
lingually) is among the most effective vaccination protocols, but increased mortality was still
observed. In the groups immunized subcutaneously with FC/lysate and CCR4 antagonist/
lysate, a significant protection was observed. Compared to the FC/lysate immunized group,
gastric pseudo-pyloric metaplasia was less severe or even absent in the CCR4 antagonist/
lysate immunized group. In general, an inverse correlation was observed between IFN-γ,
IL-4, IL-17, KC, MIP-2 and LIX mRNA expression and H. suis colonization density, whereas
lower IL-10 expression levels were observed in partially protected animals.
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Introduction
Helicobacter suis (H. suis) is a Gram-negative, spiral-shaped bacterium and a worldwide spread
pathogen colonizing the stomach of up to 90% of slaughter pigs. Even higher colonization rates
are observed in adult boars and sows [1]. Infection withH. suis causes gastritis and a decrease
in daily weight gain [2]. Although not always straightforward, several studies attribute a role to
this pathogen in the development of gastric ulcer disease in pigs [2]. Economic losses due to
the stomach ulcerations are believed to be substantial [3].H. suis is also of zoonotic impor-
tance. Infection in human patients has been associated with gastritis, peptic ulceration and
mucosa associated lymphoid tissue lymphoma [3].
Vaccination is considered to be a potentially valuable approach to control gastric Helicobac-
ter infections and related disease development [4]. Besides the use of the appropriate antigen or
combination of antigens, the choice of the immunization route and adjuvant play an important
role in the outcome of vaccination studies. The use of an appropriate adjuvant has several bene-
fits. Among other things, it reinforces the immune response, providing better and longer last-
ing protection against the pathogen. An adjuvant also allows the dose and dosing schedule of
the antigen(s) to be decreased and modulated, reducing the cost and logistical complexity of
administering vaccines [5]. MostHelicobacter vaccination strategies have been designed to gen-
erate an optimal immune response at the mucosal surface, in line with strategies applied for
other mucosal bacterial infections [4]. As adjuvants for mucosal immunization, Cholera Toxin
(CT) and the heat-labile toxin of enterotoxigenic Escherichia coli (LT) have been the most
widely used in mice, although they are known to have side-effects in humans, such as the devel-
opment of diarrhoea, even at low doses [6,7,8,9,10,11,12,13]. Several other adjuvants have also
been used in H. pylori vaccination studies. These include linear polysaccharides such as chito-
san [14] and immunostimulatory CpG oligonucleotides [15,16]. Different vaccination proto-
cols against H. pylori have already been tested in different animal models. They usually
resulted in a reduction in the number of bacteria colonizing the stomach but few strategies con-
ferred protection in terms of sterilizing immunity [17].
In a previousH. suis vaccination study in mice, prophylactic intranasal immunization with CT
adjuvantedH. suis whole-cell lysate resulted in a minority of animals beingH. suis negative, as
shown by conventional PCR [18]. However, increased mortality rates were observed in these vac-
cinated and challenged animals. This side-effect has not been thoroughly investigated yet. In addi-
tion to increased mortality rates, intranasal vaccination with a CT adjuvanted subunit vaccine
consisting of a combination of differentH. suis proteins including theH. suis ureB and GGT,
induced post-vaccination gastritis as another major side-effect. This has also been described inH.
pylori vaccination studies and its role in protection remains largely unclear [19]. Besides CT adju-
vanted vaccines, a saponin-based adjuvantedH. suiswhole-cell lysate has been tested in mice.
This vaccine formulation was administered subcutaneously and although it induced less severe
adverse effects, its protective efficacy was shown to be inferior to CT based vaccine formulations.
Recent studies describe the adjuvant activity of small molecule CC chemokine receptor 4
(CCR4) antagonists [20,21]. CCR4 is expressed on regulatory T-cells (Tregs) and Th2 cells and
regulates the migration of these T cell subsets in response to MDC (macrophage derived che-
mokine, CCL22) and TARC (thymus and activation-related chemokine, CCL17) [22,23]. CD4+
Tregs express high levels of CD25 (IL-2Rα) and actively control or suppress the function of
both innate and adaptive immune cells [17]. One of the most important cytokines secreted by
these Tregs is the anti-inflammatory interleukin-10 (IL-10) [24]. Therefore, IL-10-producing
Tregs play a role in suppressing inflammation-related pathological changes. This mechanism
is, however, most likely also involved in persistence ofH. suis infection in its hosts due to sup-
pression of immune responses [18,19].
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CCR4 antagonists have been described to amplify cellular and humoral immune responses
in vivo in experimental models when injected in combination withMycobacterium or Plasmo-
dium yoelii vaccine antigens [5,21]. In addition, CCR4 antagonists induced antigen-specific
CD8+ T-cells and tumor immunity against self-antigens [25]. Thus far, this promising adjuvant
has not been tested in vaccination and challenge studies involving pathogens. The CCR4 antag-
onist AF-399/42018025 used in this study is a small chemical molecule with a molecular weight
of 565.93. It contains six 5 or 6 membered aromatic rings and 3 nitrogen, sulfur, and oxygen
atoms. The chemical name of the molecule is 4-(1-benzofuran-2-ylcarbonyl)-1-{5-[4-chloro-
benzyl)sulfanyl]-1,3,4-thiadiazol-2-yl}-3-hydroxy-5-(2-thienyl)-1,5-dihydro-2H-pyrrol-2-one
[5]. (Fig 1. The chemical structure of the CCR4 antagonist).
The purpose of the first study was (1) to explore the efficacy of several established vaccine
adjuvants (CpG-DNA, Curdlan, Freund’s complete (FC), Freund’s incomplete (FIC) and CT)
administered subcutaneously or intranasally along withH. suis lysate to protect againstH. suis
challenge in mice and (2) to assess the adverse effects associated with these vaccination proto-
cols. Since substantial side effects were observed in all vaccination strategies, a second study
was performed, aiming at reducing these unwanted side effects. Administered vaccine volumes
as well as routes of administration were modified and a new adjuvant, a CCR4-antagonist, was
included.
Materials and Methods
Animals
In a first study, a total of 96 seven-week-old female Helicobacter specific pathogen-free BALB/c
mice were purchased from an authorized breeder (HARLAN, Horst, The Netherlands). The
animals were housed on autoclaved wood shavings in filter top cages. They were fed an auto-
claved commercial diet (TEKLAD 2018 S, HARLAN). In a second study, a total of 66 seven-
week-old female Helicobacter spp-free BALB/c mice were used. All animal experiments were
approved by the Ethics Committee of the Faculty of Veterinary Medicine, Ghent University
(EC2010/043 and EC2013/024). The animals were monitored several times a day during the
whole experiment. When the animals were visibly less active, lost weight or showed symptoms
of illness, the weight of the animal was compared with the other animals of the group. When a
decrease of 20% of the body weight was observed, the animal was euthanized.
Antigens for immunization
H. suis strain HS5bLP, isolated from the gastric mucosa of a sow [26], was grown on Brucella
agar (Oxoid, Basingstoke, UK) supplemented with 20% fetal calf serum, 5 mg amphotericin B/l
Fig 1. The chemical structure of the CCR4 antagonist. The CCR4 antagonist AF-399/42018025 is a small
chemical molecule with a molecular weight of 565.93. It contains containing six 5 or 6 membered aromatic
rings and 3 nitrogen, sulfur, and oxygen atoms. The chemical name of the molecule is 4-(1-benzofuran-
2-ylcarbonyl)-1-{5-[4-chlorobenzyl)sulfanyl]-1,3,4-thiadiazol-2-yl}-3-hydroxy-5-(2-thienyl)-1,5-dihydro-2H-
pyrrol-2-one [5].
doi:10.1371/journal.pone.0131364.g001
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(Fungizone; Bristol-Myers Squibb, Epernon, France), Campylobacter selective supplement
(Skirrow, Oxoid; containing 10 mg/l vancomycin, 5 mg/l trimethoprim lactate and 2500 U/l
polymyxin B) and Vitox supplement (Oxoid). In addition, the pH of the agar was adjusted to 5
by adding HCl to a final concentration of approximately 0.05%. Brucella broth (Oxoid) with a
pH of 5 was added on top of the agar to obtain biphasic culture conditions. After 3 days of
incubation at 37°C under microaerobic conditions (85% N2, 10% CO2, 5% O2), the Brucella
broth, containing the bacteria, was harvested [18]. Bacteria were washed, concentrated by cen-
trifugation (5000g, 10 min, 4°C) and suspended in phosphate buffered saline (PBS). The bacte-
rial suspension was sonicated 8 times for 30 seconds, with a frequency of 20 kHz (Sonicator
ultrasonic processor XL 2015; MISONIX, Farmingdale, USA), resulting in lysis of the bacteria
[18]. After centrifugation (13,000g, 10 min, 4°C), the supernatant fluid was collected and stored
at -70°C until further use.
Preparation of the challenge material
For the challenge of the mice, H. suis strain HS5bLP was cultured as described above. The final
concentration was determined by counting the bacteria in an improved Neubauer counting
chamber.
Immunization/challenge study design
In the first study, the mice were divided into 10 groups (Table 1) and in the second study, 11
groups of mice were used (Table 2). In both studies, immunizations were performed under
light isoflurane anaesthesia (IsoFlo; Abbott, Il, USA) on days 7, 14 and 35 after arrival. Appro-
priate controls were included consisting of sham-immunized mice that were either challenged
(positive controls) or not (negative controls) (see Tables 1 and 2). For sham-immunization,
Hank’s Balanced Salt Solution (HBSS; Invitrogen, Paisley, England) was used.
Table 1. Experimental set-up Study 1.
Immunization1 Administration route2 Adjuvant/mouse3 Total volume administered4 Challenged5 Number of animals6
1 Neg. Control IN / 15 μl No 6
SC / 100 μl No 6
2 FC SC 50 μl 100 μl Yes 12
3 FIC SC 50 μl 100 μl Yes 12
4 Curdlan SC 200 μg 100 μl Yes 12
5 CT IN 5 μg 15 μl Yes 12
6 CpG-DNA IN 20 μg 15 μl Yes 12
7 Curdlan IN 200 μg 15 μl Yes 12
8 Pos. Control IN / 15 μl Yes 6
SC / 100 μl Yes 6
Shown is the
1immunization protocol
2the administration route of the vaccine
3the amount of adjuvant used per mouse
4the volume of the vaccine
5the amount of lysate as shown by the protein concentration used per mouse
6whether the animals were challenged with H. suis or not and 6the number of animals in each group. (FC: Freund’s complete, FIC: Freund’s incomplete,
CT: Cholera toxin, IN: intranasally, SC: subcutaneously, Pos. control.: sham-immunized/challenged, Neg. control: sham-immunized/not challenged)
doi:10.1371/journal.pone.0131364.t001
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Several adjuvants were used, inducing different immune responses. Curdlan is known to
elicit a predominant Th17 response [27]. CpG-DNA and Freund’s complete are known to elicit
a predominant Th1 response, whereas Freund’s incomplete and Cholera toxin elicit a predomi-
nant Th2 response [28]. In the first study, subcutaneous vaccination was done by mixing
100 μg of H. suis sonicate (in a volume of 50 μl) with an equal volume of FC (Sigma-Aldrich,
St. Louis, MO, USA), FIC (Sigma-Aldrich, St. Louis, MO, USA) or 200 μg Curdlan (Sigma-
Aldrich, St. Louis, MO, USA). This mixture was injected at the lower back of the animals. For
intranasal vaccination, a total volume of 15 μl was used, containing 100 μg of H. suis sonicate
mixed with 5 μg CT (Sigma-Aldrich, St. Louis, MO, USA), 20 μg CpG-DNA (Hycult, biotech,
The Netherlands) or 200 μg Curdlan (Sigma-Aldrich, St. Louis, MO, USA). The mixture was
then applied on the external nares of the mice.
In the second study, subcutaneous vaccination was done by mixing 100 μg of H. suis soni-
cate with 1.5 μg CCR4 antagonist or 50 μl FC. For sublingual and intranasal vaccination, a total
volume of 7 μl was used, containing 100 μg ofH. suis sonicate mixed with 5 μg CT or 1.5 μg
CCR4 antagonist.
On day 56 of both studies, the mice were intragastrically inoculated with 0.3 ml of the chal-
lenge material, containing approximately 2 x 108 viable H. suis bacteria/ml, using a ball-tipped
gavage needle. The mice were held in an upright position until they regained consciousness, to
minimize the risk of reflux.
In both studies, all animals were euthanized on day 77 by cervical dislocation under deep
isoflurane anaesthesia (IsoFlo; Abbott, Il, USA). The stomachs were removed and preserved in
RNAlater (Ambion, Austin, TX, USA) at -70°C until DNA and RNA extraction. A longitudinal
strip of tissue taken along the curvatura major of the stomach was fixed in phosphate buffered
formaline (4%) for histopathological analyses. For DNA and RNA isolation, the stomachs were
homogenized in 1 ml Tri-reagent (MRC, Brunschwig Chemie, Amsterdam, The Netherlands)
Table 2. Experimental set up Study 2.
Immunization1 Administration route2 Adjuvant/mouse3 Total volume administered4 Challenged5 Number of animals6
1 Neg. Control IN / 7 μl No 6
2 HBSS/CCR4 SC 1.5 μg 100 μl Yes 6
3 HBSS/CCR4 IN 1.5 μg 7 μl Yes 6
4 HBSS/CCR4 SL 1.5 μg 7 μl Yes 6
5 CT/lysate IN 5 μg 7 μl Yes 6
6 CT/lysate SL 5 μg 7 μl Yes 6
7 FC/lysate SC 50 μl 100 μl Yes 6
8 CCR4/lysate IN 1.5 μg 7 μl Yes 6
9 CCR4/lysate SL 1.5 μg 7 μl Yes 6
10 CCR4/lysate SC 1.5 μg 100 μl Yes 6
11 Pos. Control IN / 7 μl Yes 6
Shown is the
1immunization protocol
2the administration route of the vaccine
3the amount of adjuvant used per mouse
4the volume of the vaccine
5the amount of lysate as shown by the protein concentration used per mouse
6whether the animals were challenged with H. suis or not and 6the number of animals in each group. (HBSS: Hank’s balanced salt solution, CCR4: CC
chemokine receptor 4 antagonist, CT: Cholera toxin, FC: Freund’s complete, IN: intranasally, SC: subcutaneously, SL: sublingually, Neg. control: sham-
immunized/not challenged, Pos. control: sham-immunized/challenged,)
doi:10.1371/journal.pone.0131364.t002
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using a MagnaLyser (Roche Applied Science, Mannheim, Germany). The interphase and
organic phase were kept at -20°C for subsequent DNA extraction according to the instructions
of the manufacturer. Meanwhile, total RNA was extracted from the upper aqueous phase using
the RNeasy mini kit (Qiagen, Venlo, The Netherlands).
Quantitative Real-Time PCR for the quantification of the bacteria
Quantitative Real-Time PCR (RT-PCR) was performed using the C1000 Thermal cycler (CFX96
Real-Time System, Bio-Rad, Hercules, CA, USA). Each sample contained 5 μl of iQ SYBR Green
Supermix (Bio-Rad), 0.25 μl of each primer, 3.5 μl of distilled water and 1 μl of DNA.
For enumeration of colonizingH. suis bacteria in the first study, a 218 bp fragment of the
ureB gene ofH. suiswas amplified using the following primers: sense primer: 5’-TTA CCA AAA
ACA CCG AAG CC-3’, antisense primer: 5’-CCA AGT GCG GGT AAT CAC TT-3’. A 1146 bp
PCR fragment of the ureB gene served as an external standard (sense primer: 5’- CGG GAT TGA
TAC CCA CAT TC-3’; antisense primer: 5’- ATG CCG TTT TCA TAA GCC AC-3’) [29].
For enumeration of colonizing bacteria in the second study, a fragment of the UreA gene of
H. suis was amplified using the following primers: sense primer BF_HsuisF1: 50-AAA ACA
MAG GCG ATC GCC CTG TA-30 and anti-sense primer BF_HsuisR1: 50-TTT CTT CGC
CAG GTT CAA AGC G-30. For generating the standard, part of the ureAB gene cluster (1236
bp) fromH. suis strain HS5 was amplified using primers U430F and U1735R, as described pre-
viously [30].
The copy number concentration was calculated based on the length of the amplicon and the
mass concentration. The standard consisted of 10-fold dilutions starting at 107 PCR amplicons
for each 10 μl of reaction mixture. Data analysis was done using the Bio-Rad CFXManager
Version 3.0 software (Bio-Rad).
Quantitative Real-Time PCR for the analysis of cytokine and chemokine
expression
Messenger RNA expression levels in stomach tissue were determined for the following genes:
IL-17, IL-4, IFN-γ, keratinocyte chemoattractant (KC or CXCL1), LPS-induced CXC chemo-
kine (LIX), macrophage inflammatory protein-2 (MIP-2 or CXCL2) and IL-10. For the
RT-PCR reaction, a C1000 Thermal cycler (CFX96 Real-Time System, Bio-RAD, Hercules,
CA, USA) was used. All reactions were performed in a final volume of 10 μl containing 5
pmole of the sense and 5 pmole of the antisense primers, 5 μl iQ SYBR mix (Bio-Rad) and 1 μl
cDNA. The reaction protocol consisted of an initial activation phase at 95°C for 15 minutes fol-
lowed by 40 cycles of 95°C for 20 seconds, 60°C for 30 seconds and 73°C for 30 seconds. A
melting curve was included by increasing the temperature with 0.5°C every 5 seconds starting
from 65°C until 95°C. The housekeeping genes H2afz, PPIA and HPRT were shown to have a
stable expression in all samples tested (data not shown) and were included as references. The
sequences of all used primers are summarized in Table 3.
The threshold cycle values (Ct) were first normalized to the geometric means of the refer-
ence genes and the normalized mRNA levels were calculated according to 2(-ΔΔCt) method for
each individual animal [31].
Histopathological evaluation of the gastric wall
Samples of the gastric wall were formalin-fixed, paraffin wax embedded, cut at 5 μm and
stained with hematoxylin and eosin according to standardized protocols. Inflammation (infil-
tration of granulocytes as well as mononuclear cells) was scored separately for the mucosa and
submucosa, using a scoring system adapted from the human updated Sydney System [32].
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Scoring of inflammatory cell infiltration was performed as follows: 0 = normal, 1 = multifocal
mild, 2 = diffuse mild or multifocal moderate, 3 = diffuse mild and (multi)focal moderate,
4 = diffuse moderate or multifocal severe, 5 = diffuse moderate and (multi)focal severe, 6 = dif-
fuse severe. Numbers of globular leukocytes were scored as follows: 0 = no globular leukocytes,
1 = mild increase in globular leukocyte numbers, 2 = moderate increase in globular leukocyte
numbers, 3 = severe increase in globular leukocyte numbers. In the second study, the presence
of lymphocyte and neutrophil infiltration in the mucosa of the fundus was scored separately as
follows: 0 = normal, 1 = mild, 2 = moderate, 3 = severe. In addition, Periodic acid-Schiff (PAS)
staining was performed to evaluate the presence of pseudo pyloric metaplasia of the fundus.
Statistical analysis
For all analyses, SPSS 22 (IBM, USA) was used. Differences inH. suis colonization and cytokine
expression among groups were assessed by using one-way ANOVA analysis. A Bonferroni
post-hoc test was used for comparisons between the different groups. Histological inflamma-
tion scores were compared by a Kruskal-Wallis analysis, followed by a Mann-Whitney U test.
For correlations between different variables, Spearman’s rho coefficient (ρ) was calculated. A
level of probability of 0.05 was used as criterion for significance.
Results
Cholera toxin, Freunds’ complete adjuvant and CCR4 antagonists
confer the highest level of protection against colonizing H. suis bacteria
In the first study, all immunization strategies with various adjuvants and routes of immuniza-
tion (i.e. subcutaneous immunization with FC, FIC, Curdlan or intranasal immunization
with CT, CpG and Curdlan) resulted in the reduction of bacterial burden followingH. suis
Table 3. List of genes and sequences of the primers used for RT-PCR gene expression analysis [28].
Gene Primer Primer Sequence
IFN-γ sense 5'-GCG TCA TTG AAT CAC ACC TG-3'
antisense 5'-TGA GCT CAT TGA ATG CTT GG-3'
IL-4 sense 5'-ACT CTT TCG GGC TTT TCG AT-3'
antisense 5'-AAA AAT TCA TAA GTT AAA GCA TGG TG-3'
IL-10 sense 5'-ATC GAT TTC TCC CCT GTG AA-3'
antisense 5'-CAC ACT GCA GGT GTT TTA GCT CC-3'
IL-17 sense 5'-TTT AAC TCC CTT GGC GCA AAA-3'
antisense 5'-CTT TCC CTC CGC ATT GAC AC-3'
KC sense 5'-GCT GGG ATT CAC CTC AAG AA-3'
antisense 5'-TCT CCG TTA CTT GGG GAC AC-3'
MIP-2 sense 5'-AAA GTT TGC CTT GAC CCT GA-3'
antisense 5'-TCC AGG TCA GTT AGC CTT GC-3'
LIX sense 5'-CCC TGC AGG TCC ACA GTG CC-3'
antisense 5'-TGG CCG TTC TTT CCA CTG CGA-3'
H2afz sense 5’-CGT ATC ACC CCT CGT CAC TT-3’
antisense 5’-TCA GCG ATT TGT GGA TGT GT-3’
PPIA sense 5’-AGC ATA CAG GTC CTG GCA TC-3’
antisense 5’-TTC ACC TTC CCA AAG ACC AC-3’
HPRT sense 5’-CAG GCC AGA CTT TGT TGG AT-3’
antisense 5’-TTG CGC TCA TCT TAG GCT TT-3’
doi:10.1371/journal.pone.0131364.t003
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challenge, when compared to the sham-immunized/challenged animals (Fig 2). However, strik-
ing differences were observed among various adjuvants in their capacity to decrease the
amount of colonizingH. suis bacteria. Subcutaneous FC/lysate (p<0.05) administration and
intranasal CT/lysate (p<0.001) administration were the only to induce significant protection.
(Fig 2. The protective efficacy of different adjuvants on the amount of colonizing H. suis bacte-
ria, 3 weeks after challenge in study 1)
The results obtained with CT/lysate were also confirmed in the second study, wherein the
intranasal as well as sublingual route of immunization conferred the highest protection against
colonization ofH. suis in the stomach (P<0.001) (Fig 3). In addition, animals subcutaneously
immunized with FC/lysate and CCR4 antagonist/lysate showed significantly lowerH. suis colo-
nization levels after experimental challenge (P<0.01). In contrast, mucosal immunization with
CCR4 antagonists (both intranasally and sublingually) and lysate showed no significant
decrease in bacteria colonizing the stomach. Colonization levels in animals that were adminis-
trated the CCR4 antagonist in the absence of lysate and that were subsequently challenged,
were similar to those in the sham-immunized and challenged positive control animals. (Fig 3.
The protective efficacy of the different immunization protocols on the amount of colonizingH.
suis bacteria, 3 weeks after challenge in study 2)
Mice immunized with CCR4 antagonists display minimal pseudo-pyloric
metaplasia as compared to the Freund’s complete adjuvant group upon
challenge with H. suis
In both studies, a number of animals died in each group immunized with CT (both intranasally
and sublingually), within 48 hours after challenge with H. suis. The most likely cause was an
Fig 2. The protective efficacy of different adjuvants on the amount of colonizingH. suis bacteria, 3
weeks after challenge, in study 1. Subcutaneous immunization (SC) was done by mixingH. suis sonicate
with Freund’s complete (FC), Freund’s incomplete (FIC) or Curdlan (Curd) and injecting this mixture at the
lower back of the mice. Intranasal immunization (IN) was done by mixingH. suis sonicate with Cholera toxin
(CT), CpG-DNA (CpG) or Curdlan (Curd) and applying this mixture on the external nares of the mice. Animals
in the control groups were sham-immunized with Hank’s Balanced Salt Solution (HBSS). The bacterial load is
illustrated as log(10) of H. suis copies/mg stomach tissue. Individual mice are illustrated as dots. Significant
differences between immunized and non-immunized challenged animals are noted by * (p<0.05). (con:
uninfected, inf: infected).
doi:10.1371/journal.pone.0131364.g002
Effect of Different Adjuvants onH. suis Vaccination
PLOS ONE | DOI:10.1371/journal.pone.0131364 June 26, 2015 8 / 19
immunization/challenge related pneumonia, for histopathological evaluation showed the pres-
ence of oedema in the interstitial space of the lungs of these mice. In the first study, two mice
from the Curdlan/intranasally vaccinated group died before challenge, and one mouse from
the CpG/intranasally vaccinated group died of an unknown cause at week eleven following
challenge.
In both studies, all negative control mice showed normal histomorphology with very little
to no inflammatory cell infiltration in the gastric mucosa (Fig 4). All positive control groups
showed moderate to severe inflammation. (Fig 4. H&E and PAS staining of a normal fundus)
In the first study, mice immunized subcutaneously with FIC/lysate, FC/lysate and Curdlan/
lysate clearly showed a stronger infiltration of granulocytes in the fundic mucosa and submu-
cosa (p<0.05) (Table 4) as compared to animals from the intranasally immunized/challenged
groups. Detection of globular leukocytes was restricted to the mucosa of the subcutaneously
immunized groups. In addition, all immunized and challenged groups showed moderate lym-
phocyte infiltration, and this was most pronounced in the group immunized with CT/lysate
(Table 4).
Fig 3. The protective efficacy of the different immunization protocols on the amount of colonizingH.
suis bacteria, 3 weeks after challenge, in study 2. Subcutaneous immunization (SC) was done by mixing
H. suis sonicate with Freund’s complete (FC) or the CCR4 antagonist (CCR4) and injecting this mixture at the
lower back of the mice. Intranasal immunization (IN) was done by mixingH. suis sonicate with Cholera toxin
(CT) or the CCR4 antagonist (CCR4) and applying this mixture on the external nares of the mice. Sublingual
immunizations (SL) were done by mixingH. suis sonicate with Cholera toxin (CT) or the CCR4-antagonist
(CCR4). Animals in the control groups were sham-immunized with Hank’s Balanced Salt Solution (HBSS).
The amount of bacteria colonizing the stomach of the mice are illustrated as log(10) of H. suis copies/mg
stomach. The individual animals are presented as dots. Significant differences between the immunized and
challenged groups and the positive control group are noted by ** (p<0.01) and *** (p<0.001). (neg. con.:
sham-immunized/not challenged, pos. con.: sham-immunized/challenged).
doi:10.1371/journal.pone.0131364.g003
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Results from the second study revealed that, compared to the positive control group, mice
that received CT/lysate by the sublingual route showed significantly increased neutrophil infil-
tration in the fundus (p<0.01) upon challenge withH. suis. In addition, compared to the posi-
tive control groups, lymphocyte infiltration was significantly increased in all the immunized
and challenged groups except for the groups immunized with the CCR4 antagonist/lysate by
sublingual and intranasal routes (Table 5).
Interestingly, in the first study, pseudo-pyloric metaplasia was detected in the stomach of
75% of the mice from the FC/lysate immunized and challenged group and even in 100% of the
animals belonging to the FIC/lysate and SC Curdlan/lysate immunized and challenged animals.
In all other groups, no pseudo-pyloric metaplasia was observed (Fig 5). In the second study,
pseudo-pyloric metaplasia of the fundus was present in the group immunized with FC/lysate
and CT/lysate/SL and challenged (Fig 6). Although pseudo-pyloric metaplasia was also present
in the CCR4 antagonist/lysate/SC immunized and challenged group (Fig 7), this was neverthe-
less less severe and not present in all animals, compared to the group immunized with FC/
lysate (Table 5). (Fig 5. Histopathological analysis of fundus by H&E staining, Fig 6. H&E and
PAS staining of the fundus showing pronounced inflammation and severe pseudo-pyloric
metaplasia, Fig 7. H&E and PAS staining of the fundus, showing mild inflammation and
pseudo-pyloric metaplasia)
Fig 4. H&E and PAS staining of a normal fundus.H&E (A) and PAS staining (B) of a normal fundus of an
animal from the negative control group (original magnification: 100x).
doi:10.1371/journal.pone.0131364.g004
Table 4. Histopathological scoring of inflammation Study 1.
Pseudo-pyloric metaplasia Granulocyte inﬁltration Mononuclear cell inﬁltration
HBSS/sc/con 0 (0–0) 0 (0–1) 0 (0–0.5)
HBSS/in/con 0 (0–0) 0 (0–0) 0 (0–0.5)
HBSS/sc/inf 0 (0–0) 1 (0.5–1) 0.5 (0.5–1.5)
HBSS/in/inf 0 (0–0) 1 (0.5–2.5) 1.5 (0.5–1.5)
FC/lysate/SC 2.5 (0–3)* 1.5 (0.5–2)* 0.5 (0.5–1)
FIC/lysate/SC 3 (3–3)* 1.5 (0,5–2)* 0.5 (0–0.5)
Curd/lysate/SC 3 (3–3)* 1.5 (0.5–2)* 0.5 (0.5–1)
CT/lysate/IN 0 (0–0) 0.5 (0–0.5) 0.5 (0.5–1)
CpG/lysate/IN 0 (0–0) 0 (0–1) 0.5 (0.5–1)
Curd/lysate/IN 0 (0–0) 0 (0–0.5) 0.5 (0.5–0.5)
Shown are the median scores (min-max) of pseudo-pyloric metaplasia of the fundus, inﬁltration of the mucosa of the fundus with granulocytes and
mononuclear cells 3 weeks after challenge of the vaccinated mice. Scoring: 0 = normal, 1 = mild, 2 = moderate, 3 = severe. Signiﬁcant differences
between the positive control group and the immunized and challenged groups are noted by
* (p<0.05). (HBSS: Hank’s balanced salt solution FC: Freund’s complete, FIC: Freund’s incomplete, CT: Cholera toxin, Curd: Curdlan, CpG: CpG-DNA IN:
intranasally, SC: subcutaneously, con: uninfected group, inf: infected group)
doi:10.1371/journal.pone.0131364.t004
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Immunization with adjuvants modulates the cytokine responses in the
stomach upon H. suis challenge
In the first study, data from immunized/challenged groups were compared to pooled data from
the sham-immunized/challenged positive control groups (Fig 8). Expression of IL-10, an
important immunoregulatory cytokine, was significantly lower in all the adjuvant groups as
compared to the sham-immunized and challenged groups (p<0.0001). In the subcutaneously
immunized/challenged groups, adjuvants showed distinct differences in their ability to mount
helper T cell responses. Although FC/lysate, FIC/ lysate and and Curdlan/lysate groups showed
significantly higher Th1 and Th2 cytokine signatures (IFN-γ; p<0.0001 and IL-4; p<0.01),
Th17 cytokine responses (IL-17) were only observed with Freund’s complete and incomplete
adjuvant groups. Mice immunized by mucosal routes displayed distinct helper T cell responses
as compared to subcutaneous immunization routes. No Th2 response (IL-4) was induced in
CT/lysate, CpG/lysate and Curdlan/lysate immunized groups, suggesting that these adjuvants
selectively induce Th1 and Th17 responses when administered by mucosal routes. Clearly,
Curdlan/lysate, irrespective of the route of vaccination, was less efficient to induce chemokine
expression as compared to Freund’s adjuvants. In all immunized/challenged animals, LIX
Table 5. Histopathological scoring of inflammation Study 2.
Pseudo-pyloric metaplasia Granulocyte inﬁltration Mononuclear cell inﬁltration
Neg. Control 0 (0–0) 0 (0–0) 0 (0–0)
CCR4/SC 0 (0–0) 1.5 (0–2) 1.5 (0–2)
CCR4/IN 0 (0–0) 0.5 (0–2) 0.5 (0–1)*
CCR4/SL 0 (0–0) 1 (0–2) 1.5 (1–2)*
CT/lysate/IN 0 (0–0) 1.5 (0–3) 2 (1–3)
CT/lysate/SL 1.5 (1–2)* 2.5 (2–3)* 3 (3–3)*
FC/lysate/SC 3 (3–3)* 1.5 (1–2) 2.5 (2–3)
CCR4/lysate/IN 0 (0–0) 1 (0–1)* 0.5 (0–1)*
CCR4/lysate/SL 0.5 (0–1) 0.5 (0–1)* 0.5 (0–1)*
CCR4/lysate/SC 2 (0–3)* 1 (1–2) 2.5 (1–3)
Pos. Control 1.5 (0–2) 1 (1–1) 2 (1–3)
Shown are the median scores (min-max) of pseudo-pyloric metaplasia of the fundus, inﬁltration of the mucosa of the fundus with granulocytes and
mononuclear cells 3 weeks after challenge of the vaccinated mice. Scoring: 0 = normal, 1 = mild, 2 = moderate, 3 = severe. Signiﬁcant differences
between the positive control group and the immunized and challenged groups are noted by * (p<0.05). (CCR4: CC chemokine receptor 4 antagonist, CT:
Cholera toxin, FC: Freund’s complete, IN: intranasally, SC: subcutaneously, SL: sublingually, Neg. control: sham-immunized/not challenged, Pos. control:
sham-immunized/challenged)
doi:10.1371/journal.pone.0131364.t005
Fig 5. Histopathological analysis of fundus by H&E staining.Normal fundus from an uninfected BALB/c
mouse (A). Metaplastic fundus of a Freund’s complete/lysate immunized andH. suis-infected BALB/c mouse,
showing severe parietal cell loss, with replacement of the intestinal epithelium by a common glandular
epithelium (B). Original magnification: 200x.
doi:10.1371/journal.pone.0131364.g005
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showed higher mRNA expression levels (p<0.05) when compared to the sham-immunized/
challenged animals. This was not the case for MIP-2 and KC. However, a clear upregulation of
MIP-2 mRNA expression levels was observed in the FC/lysate and FIC/lysate groups, while a
clear upregulation of KC expression was only observed in the FC/lysate and CT/lysate groups.
Messenger RNA expression levels of these cytokines are presented in Fig 8. (Fig 8. Relative
gene expression in the stomach in challenged animals after immunization or after sham inocu-
lation in study 1)
Similar results were obtained in the second study (Fig 9). IL-10 expression was clearly lower
in all vaccinated groups as compared to positive control groups. Of note, the use of the CCR4
antagonist by the subcutaneous route induced highest IFN-γ responses confirming the previ-
ous results obtained with this adjuvant in other models where cellular immune responses were
significantly induced [21,25]. However, Th1 responses were not induced when the CCR4
antagonist was used for mucosal immunization, a protocol which was shown not to be able to
confer protection upon challenge withH. suis. (Fig 9. Relative gene expression in the stomach
in challenged animals after immunization or after sham inoculation in study 2)
In both studies, correlation analysis showed a clear, positive correlation between IL-10
expression and H. suis colonization rates. A significant inverse correlation was found between
the mRNA expression levels of helper T cell cytokines and chemokines tested and the bacterial
load (Fig 10). (Fig 10. Correlation between cytokine expression and H. suis colonization in
study 1)
Fig 6. H&E and PAS staining of the fundus showing pronounced inflammation and severe pseudo-
pyloric metaplasia. H&E (A) and PAS staining (B) of the fundus of an animal in the FC subcutaneously
immunized and challenged group, showing pronounced inflammation and severe pseudo-pyloric metaplasia
(original magnification: 100x).
doi:10.1371/journal.pone.0131364.g006
Fig 7. H&E and PAS staining of the fundus, showingmild inflammation and pseudo-pyloric
metaplasia. H&E (A) and PAS staining (B) of the fundus of an animal from the CCR4 antagonist
subcutaneously immunized and challenged group, showing mild inflammation and pseudo-pyloric metaplasia
(original magnification: 100x).
doi:10.1371/journal.pone.0131364.g007
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Discussion
In a previous study, we showed that intranasal immunization, with a CT/H. suis lysate vaccine,
induced a partial protection against subsequent H. suis challenge, with some animals even
Fig 8. Relative gene expression of cytokines and chemokines in the stomach of challenged animals
after immunization or after sham inoculation in study 1. The first bar represents the pooled data of the
animals that were sham-immunized with HBSS (intranasally and subcutaneously) and that were not
challenged with H. suis (Neg. con). The second bar represents the pooled data of the animals that were
sham-immunized with HBSS (intranasally and subcutaneously) and that were challenged with H. suis (Pos.
con). Bars 3, 4 and 5 represent the groups of animals that were immunized subcutaneously with Freund’s
complete (FC/lysate/SC), Freund’s incomplete (FIC/lysate/SC) or Curdlan (Curd/lysate/SC) and challenged
withH. suis. Bars 6, 7 and 8 represent the animals that were immunized intranasally with Cholera Toxin (CT/
lysate/IN), CpG-DNA (CpG/lysate/IN) or Curdlan (Curd/lysate/IN) and challenged with H. suis. An * (p<0.05)
indicates a significant modulation of mRNA expression levels compared to the sham-immunized/challenged
groups. Cytokine expression between immunized and challenged groups was also compared with each
other. When no differences could be found between the different immunized groups, the same letter
designation was attributed.
doi:10.1371/journal.pone.0131364.g008
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showing no detectable H. suis colonization by conventional PCR [18]. In this same study, ani-
mals were also immunized subcutaneously using aH. suis lysate/saponin-based adjuvant vac-
cine, which clearly was shown to be inferior to the intranasal immunization protocol, with
regards to its capacity to protect against a subsequent H. suis challenge [18]. Our current results
confirm that the choice of adjuvant plays an important role in the efficacy of a vaccine formula-
tion. Indeed, subcutaneous vaccination withH. suis lysate adjuvanted with FC or with the
CCR4 antagonist induced a similar protection compared to intranasal vaccination with CT as
an adjuvant. In contrast to parenteral immunization, mucosal immunization using this CCR4
antagonist as an adjuvant did not induce a good protection against H. suis challenge. CCR4+
effector memory regulatory T cells (Tregs) have homing capacity to skin and lungs [22]. There-
fore, the use of CCR4 antagonists as molecular adjuvant is strictly dependent on the route of
immunization. It is possible that lack of migration of CCR4+ Tregs to the sublingual region
might have contributed to ineffectiveness of this route of vaccination with CCR4 antagonists.
Conflicting results have been reported when comparing the efficacy of mucosal versus systemic
immunization routes for Helicobacter vaccination, but most studies suggest that mucosal im-
munization is the better one of the two options [12,13,33]. Results from the present study how-
ever indicate that subcutaneous vaccination, using various well-established vaccine adjuvants,
in general yields the best results with regards to reduction ofH. suis colonization. The only
mucosally applied adjuvant generating similar levels of protection was CT, which was shown
to be equally effective when used for sublingual immunization (Fig 3).
In the present study, protection was obtained in mice immunized subcutaneously with FC
as adjuvant, which was accompanied by high expression rates of MIP-2, LIX and KC (Fig 8).
These chemokines are known to be involved in the recruitment of neutrophils. Indeed,
Fig 9. Relative gene expression in the stomach in challenged animals after immunization or after
sham inoculation in study 2. The first bar represents the pooled data of negative control animals that were
sham-immunized with HBSS and remained unchallenged (Neg. con). The second bar represents positive
control group where mice were sham-immunized with HBSS (intranasally and subcutaneously) and were
subsequently infected with H. suis (Pos. con). Bars 3 and 4 represent Cholera Toxin groups immunized
intranasally (CT/lysate/IN) or sublingual routes (CT/lysate/SL) and challenged withH. suis. Bar 5 represents
Freund’s complete adjuvant group (FC/lysate/SC). Bars 6 to 8 denote CCR4 antagonists group immunized
by intranasal (IN), sublingual (SL) or subcutaneous (SC) routes respectively followed by challenge with H.
suis. The letter ‘a’ indicates a significant (p<0.05) difference of mRNA expression levels compared to positive
control groups. The letter ‘b’ indicates significant (p<0.05) changes of expression levels compared to the
negative control groups.
doi:10.1371/journal.pone.0131364.g009
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infiltration with (neutrophilic) granulocytes was more pronounced in subcutaneously immu-
nized mice, both compared to intranasally immunized/challenged mice as well as sham-immu-
nized/challenged positive control animals. This however contrasts somewhat with the results
of our second study, showing an increased infiltration with neutrophils in animals immunized
mucosally using CT as an adjuvant. In any case, a more pronounced post-vaccination gastritis
was associated with a higher degree of protection observed in both studies. This is in accor-
dance with data found in literature for H. pylori vaccination [8,34,35]. However, the disparity
in gastritis between infected animals and immunized/challenged animals has been described to
disappear, showing that this is most likely a transient event [8,12]. Whether post vaccination
gastritis is also a transient event inH. suis vaccination and subsequent challenge remains to be
determined.
Compared to the non-immunized/challenged animals, IL-10 expression levels were consis-
tently lower in animals from all immunized/challenged groups. In addition, a mild positive cor-
relation between IL-10 expression and gastric H. suis colonization rates was demonstrated (Fig
10). It has been suggested thatH. suis andH. pylori suppress the generation of an efficient
immune response by inducing expression of anti-inflammatory/regulatory IL-10, which con-
tributes to the suppression of pro-inflammatory Th17 and Th1 responses [18,36]. IL-10 is one
Fig 10. Correlation between cytokine and chemokine expression andH. suis colonization in study 1.
Shown are the correlation analyses between IL-17, IL-10, MIP-2, LIX, IFN-γ and IL-4 mRNA expression
levels on the one hand and the number of H. suis bacteria colonizing stomach of mice in the immunized and
challenged groups on the other hand. Correlation was measured by Spearman’s Rho (ρ). Statistical
significance between the immunized and challenged groups and the positive control group is noted by the P-
value.
doi:10.1371/journal.pone.0131364.g010
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of the most important cytokines secreted by regulatory T-cells (Tregs), which actively control
or suppress the function of other cells. Infection of IL-10-/- mice, lacking IL-10 expression, with
H. pylori andH. felis elicited a more severe chronic gastritis compared with that seen in wild-
type mice [37], which even led to spontaneous eradication of Helicobacter infection [4,38]. Kao
et al. showed that mucosal dendritic cells induce a Treg-biased response suppressing the induc-
tion of a Th17 response, which could in part be responsible for the chronicity of the infection
[36]. Since Tregs and IL-10 may contribute to persistence of an infection withH. suis, we
hypothesized that CCR4 antagonists might help to induce protective immunity. Results of our
study indeed reveal that a significant level of protection was achieved when using the CCR4
antagonist as an adjuvant and this was associated with only a mild pseudo-pyloric metaplasia,
which was sometimes even absent. By inhibition of Treg migration at the time of vaccination
we could achieve a certain degree of protection without undesirable side effects.
A clear upregulation of IFN-γmRNA expression levels was observed in all vaccinated/chal-
lenged groups when compared to challenged control animals. In general, an inverse correlation
was observed between the bacterial load and IFN-γ expression levels. In non-immunized/H.
suis-infected mice, a persistent H. suis infection does not induce a Th1 response [29]. This indi-
cates that immunization-evoked production of IFN-γ, a signature Th1 response cytokine, most
likely plays a role in suppression and clearance ofH. suis.
The majority of the immunization protocols that induced good protection against infection
withH. suis, showed a clear upregulation of IL-17 mRNA expression levels. Delyria et al.
showed that IL-17 expression induces the production of KC, MIP-2 and LIX primarily by
murine fibroblasts and gastric epithelial cells [39]. In the present study, this relationship was
confirmed in subcutaneously immunized animals and in particular with Freund’s adjuvants.
Although a marked upregulation of IL-17 mRNA expression levels was also observed in the
group intranasally immunized with lysate and CT, this was not accompanied by an upregula-
tion of mRNA expression levels of KC, MIP-2 and LIX. Also, despite imparting protection,
subcutaneous vaccination with H. suis lysate adjuvanted with the CCR4 antagonist did not
induce Th17 responses. Therefore, the role of IL-17 in the protection against H. suis infection
requires further investigation (Figs 8 and 9).
The major side-effects concerning vaccination againstH. suis were found to be post-vacci-
nation gastritis and increased mortality rates, especially when using CT-based vaccination pro-
tocols. In this study we aimed at reducing these side effects. In all immunization protocols
using CT as an adjuvant, an increased vaccination/challenge-related mortality was observed as
compared to other adjuvants. Four mice that were immunized intranasally with CT as adjuvant
in the first study, died within 48 hours after H. suis challenge, most likely because of a pneumo-
nia, which was confirmed histopathologically. In the second study, two mice also died in each
group immunized with CT (IN and SL), within 24 hours after challenge with H. suis, most
likely of an immunization/challenge related pneumonia, despite drastically lowering the vol-
ume of the vaccines. Histopathological evaluation showed the presence of oedema in the inter-
stitial space of the lungs of these mice. In the other groups, the mortality rates were lower.
In all subcutaneously immunized/challenged groups of the first study, severe post-vaccina-
tion gastritis and pseudo-pyloric metaplasia of the stomach epithelium were observed. In the
second study, pseudo-pyloric metaplasia was most pronounced in the groups immunized with
CT/lysate/SL and FC/lysate/SC. Interestingly, in the CCR4 antagonist/lysate/SC immunized
animals, showing a similar level of protection, this pseudo-pyloric metaplasia was shown to be
less severe and sometimes even absent. This clearly warrants further studies with CCR4 antago-
nists as adjuvant, aiming at further optimization of immunization protocols. Once further opti-
mized in rodent models, these studies should also be performed in pigs, which are the natural
hosts ofH. suis. Although CT was shown to induce substantial side effects in mice in the
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present study and although CT is known to be enterotoxic in humans, Cox et al. describe less
toxicity in pigs, the natural host ofH. suis. In 3 to 4 week old piglets, a dose of 1mg of CT
induced only a pasty to semiliquid diarrhea for 2h [28]. A major focus for further research
should be the use of non-toxic derivates of CT that still retain significant adjuvanticity. In addi-
tion, future research should be performed on the potential use of CCR4 antagonists in pig
vaccination.
In conclusion, subcutaneous immunization protocols with FC/lysate were shown to confer
an equally good protection against subsequent H. suis challenge compared to the previously
used CT/lysate intranasal immunization protocols, although a severe pseudo-pyloric metapla-
sia was observed as well. Interestingly, a newly developed CCR4 antagonist was shown to
induce similar levels of protection when used as a vaccine adjuvant for subcutaneous vaccina-
tion, whilst clearly triggering less side effects. Finally, the vaccination protocols that showed
good results in the current rodent model should be confirmed in a pig model.
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